In part one of this article we reviewed the modern biological oncotherapy of breast cancer and colorectal cancer. Now we report on the biological therapies that target various kinase inhibitor pathways by monoclonal antibodies or by oral kinase inhibitors in gastrointestinal stromal tumours, pancreatic cancer, head and neck cancer, lung cancer and kidney cancer. Cell surface receptors (e.g., epidermal growth factor receptor in head and neck cancer) and ligands necessary for the growth of metastases (e.g., vascular endothelial growth factor in kidney cancer) can be blocked by specifically developed monoclonal antibodies. Small molecular weight oral kinase inhibitors, e.g., imatinib and sunitinib in gastrointestinal stromal tumour, erlotinib in pancreatic cancer, erlotinib and gefitinib in lung cancer, sunitinib and sorafenib in kidney cancer, sorafenib in hepatocellular cancer block intracellular signal transduction pathways. The mTOR inhibitor temsirolimus can be used in advanced renal cell carcinoma.
|Number of pages||5|
|Journal||Lege Artis Medicinae|
|Publication status||Published - Jan 1 2008|
ASJC Scopus subject areas